DiaMedica is a biopharmaceutical company focused on developing novel therapeutic products that will dramatically improve the lives of people with Type 1 diabetes, Type 2 diabetes and other large unmet diseases. The Company's product portfolio protects and proliferates specific cells in specific organs.

The Ottawa Centre for Research and Innovation (OCRI) selected DiaMedica as one of Canada’s Top 10 Life Sciences companies for two consecutive years. Furthermore, two former presidents of the American Diabetes Association serve on the company’s scientific advisory board and support the compelling discoveries made by DiaMedica, as do other leaders in diabetes research.